Linking anemia to inflammation and cancer: The crucial role of TNFα

Balkwill, 2005, Smoldering and polarized inflammation in the initiation and promotion of malignant disease, Cancer Cell, 7, 211, 10.1016/j.ccr.2005.02.013 Balkwill, 2001, Inflammation and cancer: back to Virchow?, Lancet, 357, 539, 10.1016/S0140-6736(00)04046-0 Coussens, 2002, Inflammation and cancer, Nature, 420, 860, 10.1038/nature01322 Greten, 2004, IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer, Cell, 118, 285, 10.1016/j.cell.2004.07.013 Pikarsky, 2004, NF-kappaB functions as a tumour promoter in inflammation-associated cancer, Nature, 431, 461, 10.1038/nature02924 Szlosarek, 2003, Tumour necrosis factor alpha: a potential target for the therapy of solid tumours, Lancet Oncol, 4, 565, 10.1016/S1470-2045(03)01196-3 Szlosarek, 2006, Tumour necrosis factor-alpha as a tumour promoter, Eur J Cancer, 42, 745, 10.1016/j.ejca.2006.01.012 Yan, 2006, Therapeutic potential of cytokine and chemokine antagonists in cancer therapy, Eur J Cancer, 42, 793, 10.1016/j.ejca.2006.01.013 Bokemeyer, 2005, Anaemia in cancer patients: pathophysiology, incidence and treatment, Eur J Clin Invest, 35, 26, 10.1111/j.1365-2362.2005.01527.x Allen, 1999, Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and TNF-alpha, J Invest Med, 47, 204 Papadaki, 2002, Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy, Blood, 100, 474, 10.1182/blood-2002-01-0136 Robb, 2007, Cytokine receptors and hematopoietic differentiation, Oncogene, 26, 6715, 10.1038/sj.onc.1210756 Wickrema, 2007, Erythroid and megakaryocytic transformation, Oncogene, 26, 6803, 10.1038/sj.onc.1210763 Hodges, 2007, Pathophysiology of anemia and erythrocytosis, Crit Rev Oncol Hematol, 64, 139, 10.1016/j.critrevonc.2007.06.006 Zhao, 2006, Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway, Blood, 107, 907, 10.1182/blood-2005-06-2516 Wall, 1988, The human beta-globin gene 3′ enhancer contains multiple binding sites for an erythroid-specific protein, Genes Dev, 2, 1089, 10.1101/gad.2.9.1089 Merika, 1993, DNA-binding specificity of GATA family transcription factors, Mol Cell Biol, 13, 3999, 10.1128/MCB.13.7.3999 Morceau, 2004, GATA-1: friends, brothers, and coworkers, Ann N Y Acad Sci, 1030, 537, 10.1196/annals.1329.064 Ferreira, 2005, GATA1 function, a paradigm for transcription factors in hematopoiesis, Mol Cell Biol, 25, 1215, 10.1128/MCB.25.4.1215-1227.2005 Fujiwara, 1996, Arrested development of embryonic red cell precursors in mouse embryos lacking transcription factor GATA-1, Proc Natl Acad Sci USA, 93, 12355, 10.1073/pnas.93.22.12355 Pevny, 1991, Erythroid differentiation in chimaeric mice blocked by a targeted mutation in the gene for transcription factor GATA-1, Nature, 349, 257, 10.1038/349257a0 Rekhtman, 1999, Direct interaction of hematopoietic transcription factors PU.1 and GATA-1: functional antagonism in erythroid cells, Genes Dev, 13, 1398, 10.1101/gad.13.11.1398 Grass, 2003, GATA-1-dependent transcriptional repression of GATA-2 via disruption of positive autoregulation and domain-wide chromatin remodelling, Proc Natl Acad Sci USA, 100, 8811, 10.1073/pnas.1432147100 Andrews, 1993, Erythroid transcription factor NF-E2 is a haematopoietic-specific basic-leucine zipper protein, Nature, 362, 722, 10.1038/362722a0 Lu, 1994, Retroviral integration within the Fli-2 locus results in inactivation of the erythroid transcription factor NF-E2 in Friend erythroleukemias: evidence that NF-E2 is essential for globin expression, Proc Natl Acad Sci USA, 91, 8398, 10.1073/pnas.91.18.8398 Perkins, 2000, Fetal expression of a human Agamma globin transgene rescues globin chain imbalance but not hemolysis in EKLF null mouse embryos, Blood, 95, 1827, 10.1182/blood.V95.5.1827.004k10_1827_1833 Carswell, 1975, An endotoxin-induced serum factor that causes necrosis of tumors, Proc Natl Acad Sci USA, 72, 3666, 10.1073/pnas.72.9.3666 Aggarwal, 2003, Signalling pathways of the TNF superfamily: a double-edged sword, Nat Rev Immunol, 3, 745, 10.1038/nri1184 Aggarwal, 2006, Inflammation and cancer: how hot is the link?, Biochem Pharmacol, 72, 1605, 10.1016/j.bcp.2006.06.029 Pfeffer, 2003, Biological functions of tumor necrosis factor cytokines and their receptors, Cytokine Growth Factor Rev, 14, 185, 10.1016/S1359-6101(03)00022-4 Feldmann, 1996, Role of cytokines in rheumatoid arthritis, Annu Rev Immunol, 14, 397, 10.1146/annurev.immunol.14.1.397 Knobler, 2005, TNF-{alpha}, chronic hepatitis C and diabetes: a novel triad, QJM, 98, 1, 10.1093/qjmed/hci001 Targan, 1997, A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease, N Engl J Med, 337, 1029, 10.1056/NEJM199710093371502 Limb, 1996, Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy, Br J Ophthalmol, 80, 168, 10.1136/bjo.80.2.168 Friess, 1999, Growth factors and cytokines in pancreatic carcinogenesis, Ann N Y Acad Sci, 880, 110, 10.1111/j.1749-6632.1999.tb09515.x Haraoui, 2005, Differentiating the efficacy of tumor necrosis factor inhibitors, J Rheumatol Suppl, 74, 3 Haraoui, 2005, The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis, J Rheumatol Suppl, 72, 46 Broxmeyer, 1986, The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma, J Immunol, 136, 4487 Murase, 1987, Effect of recombinant human tumor necrosis factor on the colony growth of human leukemia progenitor cells and normal hematopoietic progenitor cells, Blood, 69, 467, 10.1182/blood.V69.2.467.467 Rusten, 1994, Tumor necrosis factor-alpha inhibits stem cell factor-induced proliferation of human bone marrow progenitor cells in vitro. Role of p55 and p75 tumor necrosis factor receptors, J Clin Invest, 94, 165, 10.1172/JCI117303 Rusten, 1995, Tumor necrosis factor (TNF)-alpha directly inhibits human erythropoiesis in vitro: role of p55 and p75 TNF receptors, Blood, 85, 989, 10.1182/blood.V85.4.989.bloodjournal854989 Means, 1990, Inhibition of human colony-forming-unit erythroid by tumor necrosis factor requires accessory cells, J Clin Invest, 86, 538, 10.1172/JCI114741 Means, 1993, Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon, J Clin Invest, 91, 416, 10.1172/JCI116216 Balkwill, 2002, Tumor necrosis factor or tumor promoting factor?, Cytokine Growth Factor Rev, 13, 135, 10.1016/S1359-6101(01)00020-X van Etten, 2003, Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors, Ann Surg Oncol, 10, 32, 10.1245/ASO.2003.03.076 Mantovani, 2000, Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites, J Mol Med, 78, 554, 10.1007/s001090000137 Yoshida, 2002, Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma, Br J Cancer, 86, 1396, 10.1038/sj.bjc.6600257 Leek, 1998, Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma, Br J Cancer, 77, 2246, 10.1038/bjc.1998.373 Partanen, 1995, Tumour necrosis factor-alpha (TNF-alpha) in patients who have asbestosis and develop cancer, Occup Environ Med, 52, 316, 10.1136/oem.52.5.316 Pfitzenmaier, 2003, Elevation of cytokine levels in cachectic patients with prostate carcinoma, Cancer, 97, 1211, 10.1002/cncr.11178 Aggarwal, 2004, Nuclear factor-kappaB: the enemy within, Cancer Cell, 6, 203, 10.1016/j.ccr.2004.09.003 Bossola, 2000, Serum tumour necrosis factor-alpha levels in cancer patients are discontinuous and correlate with weight loss, Eur J Clin Invest, 30, 1107, 10.1046/j.1365-2362.2000.00751.x Chang, 2003, Nuclear factor kappaB protects pancreatic beta-cells from tumor necrosis factor-alpha-mediated apoptosis, Diabetes, 52, 1169, 10.2337/diabetes.52.5.1169 Pahl, 1999, Activators and target genes of Rel/NF-kappaB transcription factors, Oncogene, 18, 6853, 10.1038/sj.onc.1203239 Allavena, 2008, The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages, Crit Rev Oncol Hematol, 66, 1, 10.1016/j.critrevonc.2007.07.004 Roodman, 1987, Mechanisms of erythroid suppression in the anemia of chronic disease, Blood Cells, 13, 171 Dufour, 2003, TNF-alpha and IFN-gamma are overexpressed in the bone marrow of Fanconi anemia patients and TNF-alpha suppresses erythropoiesis in vitro, Blood, 102, 2053, 10.1182/blood-2003-01-0114 Gersuk, 1998, A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome, Br J Haematol, 103, 176, 10.1046/j.1365-2141.1998.00933.x Dufour, 2001, Interferon gamma and tumour necrosis factor alpha are overexpressed in bone marrow T lymphocytes from paediatric patients with aplastic anaemia, Br J Haematol, 115, 1023, 10.1046/j.1365-2141.2001.03212.x Imagawa, 2003, A GATA-specific inhibitor (K-7174) rescues anemia induced by IL-1beta, TNF-alpha, or L-NMMA, FASEB J, 17, 1742, 10.1096/fj.02-1134fje Xiao, 2002, Tumor necrosis factor-alpha inhibits generation of glycophorin A+ cells by CD34+ cells, Exp Hematol, 30, 1238, 10.1016/S0301-472X(02)00930-X Kurzrock, 2001, The role of cytokines in cancer-related fatigue, Cancer, 92, 1684, 10.1002/1097-0142(20010915)92:6+<1684::AID-CNCR1497>3.0.CO;2-Z Capalbo, 2002, Evaluation of tumor necrosis factor-alpha and erythropoietin serum levels in B-cell chronic lymphocytic leukemia patients with anemia, Acta Haematol, 108, 84, 10.1159/000064751 Knight, 2004, Prevalence and outcomes of anemia in cancer: a systematic review of the literature, Am J Med, 116, 11S, 10.1016/j.amjmed.2003.12.008 Tas, 2002, Anemia in oncology practice: relation to diseases and their therapies, Am J Clin Oncol, 25, 371, 10.1097/00000421-200208000-00011 Caro, 2001, Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review, Cancer, 91, 2214, 10.1002/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P Pronzato, 2006, Cancer-related anaemia management in the 21st century, Cancer Treat Rev, 32, S1, 10.1016/j.ctrv.2006.04.008 Engert, 2005, Recombinant human erythropoietin in oncology: current status and further developments, Ann Oncol, 16, 1584, 10.1093/annonc/mdi307 Andrews, 2004, Anemia of inflammation: the cytokine–hepcidin link, J Clin Invest, 113, 1251, 10.1172/JCI21441 Blau, 2007, Erythropoietin in cancer: presumption of innocence?, Stem Cells, 25, 2094, 10.1634/stemcells.2007-0229 Jelkmann, 2008, Developments in the therapeutic use of erythropoiesis stimulating agents, Br J Haematol, 141, 287, 10.1111/j.1365-2141.2007.06948.x Rizzo, 2008, Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update, Blood, 111, 25, 10.1182/blood-2007-08-109488 Henke, 2003, Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial, Lancet, 362, 1255, 10.1016/S0140-6736(03)14567-9 Leyland-Jones, 2005, Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study, J Clin Oncol, 23, 5960, 10.1200/JCO.2005.06.150 Wright, 2007, Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia, J Clin Oncol, 25, 1027, 10.1200/JCO.2006.07.1514 Jelkmann, 2007, Control of erythropoietin gene expression and its use in medicine, Methods Enzymol, 435, 179, 10.1016/S0076-6879(07)35010-6 Morceau, 2006, Tumor necrosis factor alpha inhibits aclacinomycin A-induced erythroid differentiation of K562 cells via GATA-1, Cancer Lett, 240, 203, 10.1016/j.canlet.2005.09.014 Buck, 2008, Tumor necrosis factor alpha inhibits erythroid differentiation in human erythropoietin-dependent cells involving p38 MAPK pathway, GATA-1 and FOG-1 downregulation and GATA-2 upregulation, Biochem Pharmacol, 76, 1229, 10.1016/j.bcp.2008.08.025 Buck, 2009, The inhibitory effect of the proinflammatory cytokine TNFalpha on erythroid differentiation involves erythroid transcription factor modulation, Int J Oncol, 34, 853 Miwatashi, 2005, Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent, J Med Chem, 48, 5966, 10.1021/jm050165o Koury, 2002, New insights into erythropoiesis, Curr Opin Hematol, 9, 93, 10.1097/00062752-200203000-00002 Tsai, 1997, Transcription factor GATA-2 is required for proliferation/survival of early hematopoietic cells and mast cell formation, but not for erythroid and myeloid terminal differentiation, Blood, 89, 3636, 10.1182/blood.V89.10.3636 Shivdasani, 1995, Erythropoiesis and globin gene expression in mice lacking the transcription factor NF-E2, Proc Natl Acad Sci USA, 92, 8690, 10.1073/pnas.92.19.8690 Tsang, 1997, FOG, a multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentiation, Cell, 90, 109, 10.1016/S0092-8674(00)80318-9 Wadman, 1997, The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins, EMBO J, 16, 3145, 10.1093/emboj/16.11.3145 Blobel, 1998, CREB-binding protein cooperates with transcription factor GATA-1 and is required for erythroid differentiation, Proc Natl Acad Sci USA, 95, 2061, 10.1073/pnas.95.5.2061 Gregory, 1996, Functional interaction of GATA1 with erythroid Kruppel-like factor and Sp1 at defined erythroid promoters, Blood, 87, 1793, 10.1182/blood.V87.5.1793.1793 Matsumura, 2000, Biologic significance of GATA-1 activities in Ras-mediated megakaryocytic differentiation of hematopoietic cell lines, Blood, 96, 2440, 10.1182/blood.V96.7.2440